Eli Lilly And Stock Buy Hold or Sell Recommendation
| LLY Stock | USD 806.14 12.79 1.56% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Eli Lilly and is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eli Lilly and given historical horizon and risk tolerance towards Eli Lilly. When Macroaxis issues a 'buy' or 'sell' recommendation for Eli Lilly and, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Eli Lilly Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Eli and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Eli |
Execute Eli Lilly Buy or Sell Advice
The Eli recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eli Lilly and. Macroaxis does not own or have any residual interests in Eli Lilly and or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eli Lilly's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Eli Lilly Trading Alerts and Improvement Suggestions
| Over 84.0% of the company shares are owned by institutional investors | |
| On 10th of September 2024 Eli Lilly paid $ 1.3 per share dividend to its current shareholders | |
| Latest headline from nypost.com: Google execs try to calm workers worried about jobs while wearing Halloween costumes |
Eli Lilly Returns Distribution Density
The distribution of Eli Lilly's historical returns is an attempt to chart the uncertainty of Eli Lilly's future price movements. The chart of the probability distribution of Eli Lilly daily returns describes the distribution of returns around its average expected value. We use Eli Lilly and price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eli Lilly returns is essential to provide solid investment advice for Eli Lilly.
| Mean Return | 0.03 | Value At Risk | -3.47 | Potential Upside | 2.68 | Standard Deviation | 2.11 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eli Lilly historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eli Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Eli Lilly, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Eli Lilly and back and forth among themselves.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 17 M | State Farm Mutual Automobile Ins Co | 2024-06-30 | 12.6 M | International Assets Investment Management, Llc | 2024-09-30 | 12.5 M | Norges Bank | 2024-06-30 | 11 M | Bank Of America Corp | 2024-06-30 | 10.8 M | Wellington Management Company Llp | 2024-06-30 | 10.8 M | Capital Research Global Investors | 2024-06-30 | 9.1 M | Northern Trust Corp | 2024-06-30 | 8.7 M | Capital Research & Mgmt Co - Division 3 | 2024-06-30 | 7.3 M | Lilly Endowment Inc | 2024-09-30 | 96.9 M | Vanguard Group Inc | 2024-06-30 | 73.9 M |
Eli Lilly Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (258.7M) | (533.4M) | (235.9M) | (599.7M) | (1.4B) | (1.4B) | |
| Change In Cash | (5.7B) | 1.3B | 161.4M | (1.8B) | 751.6M | 789.2M | |
| Free Cash Flow | 3.5B | 4.5B | 5.4B | 4.6B | (3.2B) | (3.0B) | |
| Depreciation | 1.2B | 1.3B | 1.5B | 1.5B | 1.5B | 1.0B | |
| Other Non Cash Items | (3.4B) | (444.2M) | 1.6B | 1.1B | 2.2B | 2.4B | |
| Dividends Paid | 2.4B | 2.7B | 3.1B | 3.5B | (4.1B) | (3.9B) | |
| Capital Expenditures | 1.4B | 2.0B | 1.9B | 2.5B | 7.4B | 7.8B | |
| Net Income | 8.3B | 6.2B | 5.6B | 6.2B | 5.2B | 3.1B | |
| End Period Cash Flow | 2.3B | 3.7B | 3.8B | 2.1B | 2.8B | 3.4B | |
| Investments | 456.2M | 516.7M | (166M) | (244M) | (7.2B) | (6.8B) | |
| Change Receivables | (357M) | (996.7M) | (127.2M) | (299.6M) | (269.6M) | (283.1M) | |
| Net Borrowings | 4.7B | 291.6M | 501.4M | (62M) | (71.3M) | (67.7M) | |
| Change To Netincome | 653.3M | (270.6M) | 1.2B | (668.4M) | (601.6M) | (571.5M) |
Eli Lilly Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eli Lilly or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eli Lilly's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eli stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 1.37 | |
σ | Overall volatility | 2.07 | |
Ir | Information ratio | -0.02 |
Eli Lilly Volatility Alert
Eli Lilly and has relatively low volatility with skewness of 1.13 and kurtosis of 6.44. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eli Lilly's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eli Lilly's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eli Lilly Fundamentals Vs Peers
Comparing Eli Lilly's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eli Lilly's direct or indirect competition across all of the common fundamentals between Eli Lilly and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eli Lilly or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eli Lilly's fundamental indicators could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eli Lilly to competition |
| Fundamentals | Eli Lilly | Peer Average |
| Return On Equity | 0.65 | -0.31 |
| Return On Asset | 0.14 | -0.14 |
| Profit Margin | 0.20 % | (1.27) % |
| Operating Margin | 0.40 % | (5.51) % |
| Current Valuation | 752.77 B | 16.62 B |
| Shares Outstanding | 949.32 M | 571.82 M |
| Shares Owned By Insiders | 0.15 % | 10.09 % |
| Shares Owned By Institutions | 83.73 % | 39.21 % |
| Number Of Shares Shorted | 5.79 M | 4.71 M |
| Price To Earning | 54.92 X | 28.72 X |
| Price To Book | 55.31 X | 9.51 X |
| Price To Sales | 19.02 X | 11.42 X |
| Revenue | 34.12 B | 9.43 B |
| Gross Profit | 21.91 B | 27.38 B |
| EBITDA | 12.46 B | 3.9 B |
| Net Income | 5.24 B | 570.98 M |
| Cash And Equivalents | 2.07 B | 2.7 B |
| Cash Per Share | 2.97 X | 5.01 X |
| Total Debt | 25.23 B | 5.32 B |
| Debt To Equity | 1.58 % | 48.70 % |
| Current Ratio | 1.13 X | 2.16 X |
| Book Value Per Share | 15.82 X | 1.93 K |
| Cash Flow From Operations | 4.24 B | 971.22 M |
| Short Ratio | 2.19 X | 4.00 X |
| Earnings Per Share | 9.11 X | 3.12 X |
| Price To Earnings To Growth | 0.78 X | 4.89 X |
| Target Price | 1007.68 | |
| Number Of Employees | 43 K | 18.84 K |
| Beta | 0.42 | -0.15 |
| Market Capitalization | 777.42 B | 19.03 B |
| Total Asset | 64.01 B | 29.47 B |
| Retained Earnings | 10.31 B | 9.33 B |
| Working Capital | (1.57 B) | 1.48 B |
Note: Payment of 2142 shares by Donald Zakrowski of Eli Lilly subject to Rule 16b-3 [view details]
Eli Lilly Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eli . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 78727.27 | |||
| Daily Balance Of Power | (0.77) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 811.94 | |||
| Day Typical Price | 810.0 | |||
| Price Action Indicator | (12.19) | |||
| Period Momentum Indicator | (12.79) | |||
| Relative Strength Index | 48.05 |
About Eli Lilly Buy or Sell Advice
When is the right time to buy or sell Eli Lilly and? Buying financial instruments such as Eli Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Eli Lilly in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 166 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.